AVROBIO Q3 net loss narrows to $23M; cash runway into Q1 2024; Gaucher update Dec. 7

Tectonic Therapeutic, Inc.

2022-Q3 EPS reported -$1.85

Net loss of $23.0M vs $32.6M in Q3 2021; R&D expenses fell to $15.9M from $23.0M.
Cash and equivalents $116.0M as of Sept. 30, 2022, expected to fund operations into Q1 2024.
Received rare pediatric disease designation for AVR-RD-02 (Gaucher) and AVR-RD-04 (cystinosis) from FDA.
Patient dosing completed in collaborator-sponsored Phase 1/2 cystinosis trial; interim data show systemic effect.
Investor update on Gaucher disease program scheduled for Dec. 7, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tectonic Therapeutic, Inc. reported three and nine months ended September 30, 2022 results: net income $23.0 million.

Period: three and nine months ended September 30, 2022
Net income: $23.0 million
Result: reported results

Exact text from the filing

On November 8, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Tectonic Therapeutic, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-040396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.